Galectin Therapeutics Inc GALT
$2.97
▼ -8.05%
($-0.26)
⬇️ Below Yest. Low
🗓️ Earnings Next Week
Open
$3.26
Prev Close
$3.23
Day Range
$2.96 – $3.34
52W Range
$2.03 – $7.13
Market Cap
$195.59M
Beta
0.37
EPS (TTM)
$-0.41
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2002-09-04 |
| Shares Out. | 65,860,000 |
| Website | galectintherapeutics.com/ ↗ |
| Phone | 16786203186 |
| Employees | 9 |
| Net Income | -$5.0M |
| Total Assets | $15.8M |
| Total Liabilities | $146.0M |
| Equity | -$132.0M |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Galectin Therapeutics Inc is a publicly traded company under the ticker symbol GALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)